Similar articles

• Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.

  Lam CC, Ma ES, Kwong YL. Lam CC, et al. Am J Hematol. 2005 Aug;79(4):288-90. doi: 10.1002/ajh.20340. Am J Hematol. 2005. PMID: 16044456
• Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma.

  Trojan A, Meier R, Licht A, Taverna C. Trojan A, et al. Ann Hematol. 2002 Sep;81(9):535-7. doi: 10.1007/s00277-002-0497-9. Epub 2002 Aug 1. Ann Hematol. 2002. PMID: 12373357
• Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.

  Niparuck P, Kanoksil W, Chuncharunee S, Boonsakan P, Ungkanont A, Angchaisuksiri P, Karntisaviwat K, Apilugsanachit A, Rerkamnuatchoke B, Jootar S, Nitiyanant P, Atichartakarn V. Niparuck P, et al. Leuk Lymphoma. 2010 Nov;51(11):2120-5. doi: 10.3109/10428194.2010.505675. Epub 2010 Sep 17. Leuk Lymphoma. 2010. PMID: 20846095 No abstract available.
• Fludarabine in the treatment of lymphoproliferative malignancies.

  Feldman EJ, Keating MJ. Feldman EJ, et al. Cancer Invest. 1993;11(3):314-8. doi: 10.3109/07357909309024858. Cancer Invest. 1993. PMID: 8485654 Review. No abstract available.
• Purine analogs in lymphoproliferative disorders.

  Cheson BD. Cheson BD. Leuk Lymphoma. 1993;11 Suppl 2:153-9. doi: 10.3109/10428199309064276. Leuk Lymphoma. 1993. PMID: 7907252 Review. No abstract available.